Latent TGF-β structure and activation

Nature

Volumn 474, Issue 7351, 2011, Pages 343-351

  Shi, Minlong ^a   Zhu, Jianghai ^a   Wang, Rui ^a   Chen, Xing ^a   Mi, Lizhi ^a   Walz, Thomas ^b   Springer, Timothy A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA6 INTEGRIN; CD51 ANTIGEN; GROWTH FACTOR; LATENT TRANSFORMING GROWTH FACTOR BINDING PROTEIN; MONOMER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACTIVATION ENERGY; GROWTH; HOMEOSTASIS; MATRIX; MORPHOGENESIS; PROTEIN; SULFIDE;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CAMURATI ENGELMANN DISEASE; CRYSTAL STRUCTURE; DISULFIDE BOND; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN SECRETION; PROTEIN STRUCTURE; RECEPTOR BINDING; SEQUENCE ANALYSIS;

ACTIVINS; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CAMURATI-ENGELMANN SYNDROME; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; INTEGRINS; LATENT TGF-BETA BINDING PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; MUTATION; OLIGOPEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SWINE; TRANSFORMING GROWTH FACTOR BETA1;

SUS;

EID: 79959250326     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10152     Document Type: Article

References (46)

1. Wu, M. Y. & Hill, C. S. TGF-b superfamily signaling in embryonic development and homeostasis. Dev. Cell 16, 329-343 (2009).
2. Derynck, R. & Miyazono, K. in The TGF-b Family (edsDerynck, R. & Miyazono, K.) Ch. 2, 29-43 (Cold Spring Harbor Laboratory Press, 2008).
3. Blobe, G. C., Schiemann, W. P. & Lodish, H. F.Role of transforminggrowth factor b in human disease. N. Engl. J. Med. 342, 1350-1358 (2000). (Pubitemid 30408720)
4. Gray, A. M. & Mason, A. J. Requirement for activin A and transforming growth factor-b 1 pro-regions in homodimer assembly. Science 247, 1328-1330 (1990).
5. Annes, J. P., Chen, Y., Munger, J. S. & Rifkin, D. B. Integrin aVb6-mediated activation of latent TGF-b requires the latent TGF-b binding protein-1. J. Cell Biol. 165, 723-734 (2004).
6. Ramirez, F. & Sakai, L. Y. Biogenesis and function of fibrillin assemblies. Cell Tissue Res. 339, 71-82 (2010).
7. Yang, Z. et al. Absence of integrin-mediated TGFb1 activation in vivo recapitulates the phenotype of TGFb1-null mice. J. Cell Biol. 176, 787-793 (2007). (Pubitemid 46425539)
8. Wipff, P. J. & Hinz, B. Integrins and the activation of latent transforming growth factor b1-an intimate relationship. Eur. J. Cell Biol. 87, 601-615 (2008).
9. Aluwihare, P. et al. Mice that lack activity of aVb6- andaVb8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J. Cell Sci. 122, 227-232 (2009).
10. Munger, J. S. et al. The integrin aVb6 binds and activates latent TGF b1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319-328 (1999). (Pubitemid 29077586)
11. Yoshinaga, K. et al. Perturbation of transforming growth factor (TGF)-b1 association with latent TGF-b binding protein yields inflammation and tumors. Proc. Natl Acad. Sci. USA 105, 18758-18763 (2008).
12. Holm, L., Kaariainen, S., Rosenstrom, P. & Schenkel, A. Searching protein structure databases with DaliLite v.3. Bioinformatics 24, 2780-2781 (2008). (Pubitemid 352722625)
13. Daopin, S., Piez, K. A., Ogawa, Y. & Davies, D. R. Crystal structure of transforming growth factor-b2: an unusual fold for the superfamily. Science 257, 369-373 (1992).
14. Schlunegger, M. P. & Grutter, M. G. An unusual feature revealed by the crystal structure at 2.2A? resolution of humantransforming growth factor-b2. Nature 358, 430-434 (1992).
15. Radaev, S. et al.Ternary complex of transforming growthfactor-b1reveals isoformspecific ligand recognition and receptor recruitment in the superfamily. J. Biol. Chem. 285, 14806-14814 (2010).
16. Gentry, L. E. & Nash, B. W. The pro domain of pre-pro-transforming growth factor b1 when independently expressed is a functional binding protein for the mature growth factor. Biochemistry 29, 6851-6857 (1990). (Pubitemid 20225485)
17. Belville, C. et al. Mutations of the anti-Mü llerian hormone gene in patients with persistent Mü llerian duct syndrome: biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model. Mol. Endocrinol. 18, 708-721 (2004). (Pubitemid 38328214)
18. Walton, K. L. et al. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-b1 complex. J. Biol. Chem. 285, 17029-17037 (2010).
19. Little, S. C. & Mullins, M. C. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nature Cell Biol. 11, 637-643 (2009).
20. Lack, J. et al. Solutionstructure of the thirdTBdomain fromLTBP1provides insight into assembly of the large latent complex that sequesters latent TGF-b. J. Mol. Biol. 334, 281-291 (2003). (Pubitemid 37357267)
21. Chen, Y. et al. Amino acid requirements for formation of the TGF-b-latent TGF-b binding protein complexes. J. Mol. Biol. 345, 175-186 (2005). (Pubitemid 39572834)
22. Luo, B.-H., Carman, C. V. & Springer, T. A. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 25, 619-647 (2007). (Pubitemid 46697919)
23. Forman, J. R. & Clarke, J. Mechanical unfolding of proteins: insights into biology, structure and folding. Curr. Opin. Struct. Biol. 17, 58-66 (2007). (Pubitemid 46240817)
24. Janssens, K. et al. Camurati-Engelmann disease: reviewof the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J. Med. Genet. 43, 1-11 (2005). (Pubitemid 43099989)
25. Walton, K. L. et al. A common biosynthetic pathway governs the dimerization and secretion of inhibin andrelated transforming growth factor b (TGFb) ligands. J. Biol. Chem. 284, 9311-9320 (2009).
26. Anderson, S. B., Goldberg, A. L. & Whitman, M. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J. Biol. Chem. 283, 7027-7035 (2008).
27. Sengle, G. et al. Targeting of bonemorphogenetic protein growth factor complexes to fibrillin. J. Biol. Chem. 283, 13874-13888 (2008).
28. Cui, Y. et al. The activity and signaling range of mature BMP-4 is regulated by sequential cleavage at two sites within the prodomain of the precursor. Genes Dev. 15, 2797-2802 (2001). (Pubitemid 33042050)
29. Blanchet, M. H. et al. Cripto recruits FurinandPACE4andcontrolsNodal trafficking during proteolytic maturation. EMBO J. 27, 2580-2591 (2008).
30. Wilson, C. A. et al.Mü llerianinhibitingsubstance requires its N-terminal domainfor maintenance of biological activity, a novel finding within the transforming growth factor-b superfamily. Mol. Endocrinol. 7, 247-257 (1993). (Pubitemid 23066868)
31. Ulloa, L. et al. Lefty proteins exhibit unique processing and activate the MAPK pathway. J. Biol. Chem. 276, 21387-21396 (2001).
32. Keefe, A. D., Wilson, D. S., Seelig, B. & Szostak, J. W. One-step purification of recombinant proteins using a nanomolar-affinity streptavidin-binding peptide, the SBP-Tag. Protein Expr. Purif. 23, 440-446 (2001). (Pubitemid 34067367)
33. Zou, Z.& Sun, P. D. Overexpression of human transforming growth factor-b1using a recombinant CHO cell expression system. Protein Expr. Purif. 37, 265-272 (2004). (Pubitemid 39187961)
34. Gentry, L. E. et al. Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol. Cell. Biol. 7, 3418-3427 (1987).
35. Brunner, A. M. et al. Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta 1 (TGF beta 1) and TGF beta 2 (414) precursors and of cysteine residues within mature TGF beta 1: effects on secretion and bioactivity. Mol. Endocrinol. 6, 1691-1700 (1992).
36. Heras, B. & Martin, J. L. Post-crystallization treatments for improving diffraction quality of protein crystals. Acta Crystallogr. D 61, 1173-1180 (2005). (Pubitemid 43961288)
37. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997). (Pubitemid 27085611)
38. Kabsch, W. in International Tables for Crystallography, Vol. F: Crystallography of Biological Macromolecules (eds Rossmann, M. G. & Arnold, E. V.) Ch. 25.2.9 XDS, 730-734 (Springer, 2001).
39. Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D 58, 1948-1954 (2002). (Pubitemid 35337293)
40. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D 66, 22-25 (2010).
41. Bailey, S. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763 (1994).
42. Cowtan, K. Recent developments in classical density modification. Acta Crystallogr. D 66, 470-478 (2010).
43. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004). (Pubitemid 41742764)
44. Davis, I. W. et al. MolProbity: all-atomcontacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383 (2007).
45. Takagi, J., Petre, B. M., Walz, T. & Springer, T. A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110, 599-611 (2002). (Pubitemid 35247840)
46. Chen, X. et al. Requirement of open headpiece conformation for activation of leukocyte integrin aXb2. Proc. Natl Acad. Sci. USA 107, 14727-14732 (2010).